The clinical microbiology laboratory in the diagnosis of lower respiratory tract infections

Journal of Clinical Microbiology

Volumn 49, Issue 9 SUPPL., 2011, Pages

  Campbell, Sheldon ^a,b   Forbes, Betty A ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACID FAST BACTERIUM; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; BACTERIAL COUNT; BACTERIUM CULTURE; BACTERIUM ISOLATION; BRONCHITIS; BRONCHOSCOPY; BRONCHUS BIOPSY; BRONCHUS SECRETION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL LABORATORY; COMORBIDITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COUGHING; CROSS REACTION; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; EPITHELIUM CELL; ERADICATION THERAPY; GRAM STAINING; HAEMOPHILUS INFLUENZAE; HEALTH CARE QUALITY; HOST PATHOGEN INTERACTION; HUMAN; INFECTION CONTROL; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LABORATORY TEST; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; LUNG TUBERCULOSIS; MEDICAL HISTORY; MICROBIAL COLONIZATION; MICROBIAL CONTAMINATION; MICROBIAL IDENTIFICATION; MICROBIOLOGICAL EXAMINATION; MICROFLORA; MOLECULAR DIAGNOSIS; MORAXELLA CATARRHALIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PATHOGENESIS; PNEUMONIA; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; RESPIRATORY VIRUS; SENSITIVITY AND SPECIFICITY; SPUTUM; SPUTUM ANALYSIS; STANDARD; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TUBERCULIN TEST;

EID: 80053184403     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00789-11     Document Type: Conference Paper

References (21)

1. Alexander, T. S., and M. B. Miller. 2011. Should interferon gamma release assays become the standard method for screening patients for Mycobacterium tuberculosis infections in the United States? J. Clin. Microbiol. 49:2086-2092.
2. Boehme, C. C., et al. 2010. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 363:1005-1015.
3. Centers for Disease Control and Prevention. 2009. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb. Mortal. Wkly. Rep. 58:7-10.
4. Centers for Disease Control and Prevention. 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recommend. Rep. 59(RR-5):1-25.
5. Centers for Disease Control and Prevention. 2011. Flu report: weekly summary update. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/flu/weekly/. Accessed 15 April 2011.
6. Cystic Fibrosis Foundation. 2008. Patient registry 2008. Annual data report to the center directors. Cystic Fibrosis Foundation, Bethesda, MD.
7. Diel, R., R. Loddenkemper, and A. Nienhaus. 2010. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 137:952-968.
8. Foweraker, J. E., C. R. Laughton, D. F. Brown, and D. Bilton. 2005. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J. Antimicrob. Chemother. 55:921-927. (Pubitemid 40883177)
9. Gleckman, R., J. DeVita, D. Hilbert, C. Pelletier, and R. Martin. 1988. Sputum Gram stain assessment in community-acquired bacteremic pneumonia. J. Clin. Microbiol. 26:846-849.
10. Hauser, A. R., M. Jain, M. Bar-Meir, and S. A. McColley. 2011. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24:29-70.
11. Heineman, H. S., J. K. Chawla, and W. M. Lofton. 1977. Misinformation from sputum cultures without microscopic examination. J. Clin. Microbiol. 6:518-527. (Pubitemid 8229346)
12. Lewinsohn, D. A., M. N. Lobato, and J. A. Jereb. 2010. Interferon-gamma release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children. Curr. Opin. Pediatr. 22:71-76.
13. LiPuma, J. J. 2003. Burkholderia and emerging pathogens in cystic fibrosis. Semin. Respir. Crit. Care Med. 24:681-692.
14. LiPuma, J. J. 2010. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23:299-323.
15. Parrish, N. M., and K. C. Carroll. 2011. Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings. J. Clin. Microbiol. 49:772-776.
16. Saiman, L., J. Siegel, and the Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. 2003. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect. Control Hosp. Epidemiol. 24:S6-S53.
17. Sethi, S., and T. F. Murphy. 2008. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 359:2355-2365.
18. Sharp, S. E., et al. 2004. Cumitech 7B, Lower respiratory tract infections. Coordinating ed., S. E. Sharp. ASM Press, Washington, DC.
19. Skerret, S. J. 1997. Diagnostic testing to establish a microbial cause is helpful in the management of community-acquired pneumonia. Semin. Respir. Infect. 12:308-321.
20. Thomson, R. B. 2007. Specimen collection, transport, and processing: bacteriology. In P. R. Murray, E. J. Barron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
21. Zvezdin, B., et al. 2009. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 136:376-380.